<DOC>
	<DOCNO>NCT00306592</DOCNO>
	<brief_summary>The primary objective study evaluate safety natalizumab ( Tysabri® ) monotherapy evaluate risk hypersensitivity immunogenicity follow re-exposure natalizumab , confirm safety switch natalizumab interferon beta ( IFN-β ) , glatiramer acetate ( GA ) , multiple sclerosis ( MS ) therapy .</brief_summary>
	<brief_title>Natalizumab Re-Initiation Dosing</brief_title>
	<detailed_description>Study 101-MS-322 ( NCT00306592 ) conduct evaluate safety natalizumab monotherapy follow re-exposure natalizumab former clinical trial participant Studies C-1801 ( NCT00027300 ) , C-1802 ( NCT00030966 ) , C-1803 ( NCT00097760 ) . This study include participant North America . In parallel conduct study , similar study , 101-MS-321 ( NCT00297232 ) initiate participant Europe rest world . The primary purpose primary outcome study identical , therefore , combine Week 48 data study present . In addition , 48 week , participant 101-MS-322 ( NCT00306592 ) enter study 101-MS-321 ( NCT 00297232 ) , consider Long-Term Treatment Period 101-MS-322 ( NCT00306592 ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>MS subject complete Study C1801 ( NCT00027300 ) , C1802 ( NCT00030966 ) , C1803 ( NCT00097760 ) complete Dosing Suspension Safety Evaluation ( neurological examination magnetic resonance image [ MRI ] scan ) Considered investigator free sign symptom suggestive progressive multifocal leukoencephalopathy ( PML ) base medical history , physical examination , laboratory testing ( result Dosing Suspension Safety Evaluation Study C1808 [ NCT000276172 ] may use ) Other protocoldefined inclusion criterion may apply Considered investigator immunocompromised , base medical history , physical examination , laboratory testing ( result Dosing Suspension Safety Evaluation Study C1808 may use ) , due prior immunosuppressive treatment History persistent antinatalizumab antibody , base upon test prior natalizumab study Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
</DOC>